GSK’s PD-1 inhibitor Jemperli approved in the UK
Conditional marketing authorisation granted for the treatment of recurrent or advanced endometrial cancer
Read More
Tag: endometrial cancer
FDA approves GSK’s Jemperli for dMMR endometrial cancer
PD-1 inhibitor approved to treat patients with specific biomarker
Read More
GSK’s dostarlimab shows promise in endometrial cancer
The trial’s primary endpoints were confirmed objective response rate and duration of response
Read More
GSK’s endometrial cancer drug to be filed later this year
GlaxoSmithKline group Tesaro has presented mid-stage data indicating “robust activity” of its anti-PD-1 therapy dostarlimab in patients with advanced or recurrent endometrial cancer, with a filing now on the cards for later this year.
Read More
Aeterna Zentaris’ endometrial cancer drug fails in Phase III
A late stage clinical study of Aeterna Zentaris’ Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer has failed to meet its primary endpoint of demonstrating a statistically significant increase in survival in patients taking the drug.
Read More
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
